

News Release

February 7, 2024
Carna Biosciences, Inc.

Carna Biosciences and Carterra Jointly Present at SLAS2024

Carna Biosciences announces today that the company has presented new data investigating kinase-compound interactions using High Throughput Surface Plasmon Resonance (HT-SPR) on the Carterra LSA^{XT} at the SLAS2024 International Conference and Exhibition in Boston, USA.

Measuring kinase inhibitor kinetics is an area of growing interest to more accurately predict potency and optimal drug properties in humans. Quantitative and kinome-level binding parameter measurements combining Carna's single site biotinylated kinase and HT-SPR on the LSA^{XT} platform make it possible for researchers to conduct compound characterization for various kinase targets rapidly and efficiently.

At SLAS2024, the synergy between Carna's biotinylated kinases and Carterra's HT-SPR LSA^{XT} instrument was presented. Straightforward assay development, enabled by high quality biotinylated kinases, supported rapid screening of a library of small molecule compounds. By measuring 384 binding events per cycle, over 80,000 interactions were characterized in a 3-day run. Initial screening data combined with more detailed follow up assays provided a wealth of deep kinetic data which correlated well to activity data thus validating the accuracy of the instrument as well as the quality, activity, and stability of Carna's biotinylated kinases.

With demand for real-time, label free-binding assays in kinase drug discovery increasing, Carna is committed to accelerating our customers' drug discovery by providing our active, single site biotinylated kinase in combination with the Carterra's HT-SPR LSA^{XT} instrument for turnkey assessment of compound binding.

The poster presented at SLAS2024 is now available at :

URL: https://www.carnabio.com/output/catalog_download/27_ja.pdf

About SLAS2024

SLAS is a global, non-profit professional community made up of scientists from academia, government and industry who are collectively focused on leveraging the power of technology to achieve scientific objectives. This year's scientific program brings more than 150 scientific talks spanning nine educational tracks within life sciences, technology and laboratory automation. Sessions focus on innovative, life-changing and sometimes surprising discoveries from the last year.

For more information, please visit [SLAS2024 International Conference and Exhibition](#)

About Carterra Corporation

Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Carterra's high throughput screening and characterization technology combines patented microfluidics with real-time High Throughput Surface Plasmon Resonance (HT-SPR) and industry-leading Kinetic™ and Epitope™ Analysis and Visualization Software, delivering up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing platforms.

Carterra's HT-SPR technology provides customers with screening and characterization throughput and functionality that scales with omics-level applications, condensing months of work down to days.

Contact:

Corporate Planning

Carna Biosciences, Inc.

TEL: +81-78-302-7075

<https://www.carnabio.com/english/>